|
|
| | 2-Pyridinecarboxamide, 6-(1,1-difluoroethyl)-N-[2-[trans-4-[[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-methoxy-2H-indazol-5-yl]- Basic information |
| Product Name: | 2-Pyridinecarboxamide, 6-(1,1-difluoroethyl)-N-[2-[trans-4-[[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-methoxy-2H-indazol-5-yl]- | | Synonyms: | 2-Pyridinecarboxamide, 6-(1,1-difluoroethyl)-N-[2-[trans-4-[[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-methoxy-2H-indazol-5-yl]-;KTX-951;6-(1,1-difluoroethyl)-N-{6-methoxy-2-[(1r,4r)-4-{[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl)-7-azaspiro[3.5]nonan-7-yl]methyl}cyclohexyl]-2H-indazol-5-yl}pyridine-2-carboxamide;6-(1,1-Difluoroethyl)-N-[2-[trans-4-[[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-methoxy-2H-indazol-5-yl]-2-pyridinecarboxamide | | CAS: | 2573298-36-7 | | MF: | C46H52F2N8O6 | | MW: | 850.95 | | EINECS: | | | Product Categories: | | | Mol File: | 2573298-36-7.mol | ![2-Pyridinecarboxamide, 6-(1,1-difluoroethyl)-N-[2-[trans-4-[[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-methoxy-2H-indazol-5-yl]- Structure](CAS/20210305/GIF/2573298-36-7.gif) |
| | 2-Pyridinecarboxamide, 6-(1,1-difluoroethyl)-N-[2-[trans-4-[[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-methoxy-2H-indazol-5-yl]- Chemical Properties |
| density | 1.47±0.1 g/cm3(Predicted) | | pka | 10.75±0.40(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | 2-Pyridinecarboxamide, 6-(1,1-difluoroethyl)-N-[2-[trans-4-[[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-methoxy-2H-indazol-5-yl]- Usage And Synthesis |
| Uses | KTX-951 is an orally active IRAK4 and IMiD (Ikaros/Aiolos) substrates PROTAC degrader. KTX-951 has DC50 of 13 nM, 14 nM and 13 nM for IRAK4, Ikaros and Aiolos, respectively. TX-951 has antitumor activity.(Pink: IRAK4 ligand-12 (HY-48932); Black: Linker (HY-W382009); Blue: CRBN Ligand Pomalidomide (HY-10984))[1] | | in vivo | KTX-951 (10 mg/kg;Oral administration) has an oral bioavailability (F%) of 22% and an AUC of 2.6 μM hr in rats[1]. KTX-951 (10 mg/kg;Oral administration) has an oral bioavailability (F%) of 57% in dogs[1]. | | IC 50 | IRAK4: 3.5 nM (Kd); IRAK4: 18 nM (DC50) | | References | [1] Walker D H, et al. Degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broader activity with durable and complete regressions in MYD88 mutant lymphoma xenografts in vivo. Cancer Research, 2020, 80(16_Supplement): 5222-5222. |
| | 2-Pyridinecarboxamide, 6-(1,1-difluoroethyl)-N-[2-[trans-4-[[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-7-azaspiro[3.5]non-7-yl]methyl]cyclohexyl]-6-methoxy-2H-indazol-5-yl]- Preparation Products And Raw materials |
|